Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal

GALWAY, IRELAND--May 5, 2021--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss contract development and manufacturing organization (CDMO) Lonza Group (Basel, Switzerland) has announced a series of major projects for its Visp facility in Switzerland, including a new $218 million small molecule manufacturing complex and separate plans to double the drug substance production for Moderna's (NASDAQ:MRNA) (Cambridge, Massachusetts) COVID-19 vaccine.

Within this article: Details new small molecule plant investment, long-term COVID-19 deal with Moderna and related news